A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- Acronyms DUTHY
- 03 Apr 2019 Status changed from not yet recruiting to recruiting.
- 07 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
- 29 Nov 2018 New trial record